450 related articles for article (PubMed ID: 12183650)
1. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
Gill R; Alanine A; Bourson A; Buttelmann B; Fischer G; Heitz MP; Kew JN; Levet-Trafit B; Lorez HP; Malherbe P; Miss MT; Mutel V; Pinard E; Roever S; Schmitt M; Trube G; Wybrecht R; Wyler R; Kemp JA
J Pharmacol Exp Ther; 2002 Sep; 302(3):940-8. PubMed ID: 12183650
[TBL] [Abstract][Full Text] [Related]
2. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.
Fischer G; Mutel V; Trube G; Malherbe P; Kew JN; Mohacsi E; Heitz MP; Kemp JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1285-92. PubMed ID: 9400004
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus.
White HS; McCabe RT; Armstrong H; Donevan SD; Cruz LJ; Abogadie FC; Torres J; Rivier JE; Paarmann I; Hollmann M; Olivera BM
J Pharmacol Exp Ther; 2000 Jan; 292(1):425-32. PubMed ID: 10604979
[TBL] [Abstract][Full Text] [Related]
4. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
5. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.
Kew JN; Trube G; Kemp JA
Br J Pharmacol; 1998 Feb; 123(3):463-72. PubMed ID: 9504387
[TBL] [Abstract][Full Text] [Related]
6. The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens.
Kosowski AR; Liljequist S
J Pharmacol Exp Ther; 2004 Nov; 311(2):560-7. PubMed ID: 15256539
[TBL] [Abstract][Full Text] [Related]
7. Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.
Coughenour LL; Barr BM
J Pharmacol Exp Ther; 2001 Jan; 296(1):150-9. PubMed ID: 11123375
[TBL] [Abstract][Full Text] [Related]
8. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.
Peeters M; Gunthorpe MJ; Strijbos PJ; Goldsmith P; Upton N; James MF
J Pharmacol Exp Ther; 2007 May; 321(2):564-72. PubMed ID: 17267580
[TBL] [Abstract][Full Text] [Related]
9. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
Williams K
Mol Pharmacol; 1993 Oct; 44(4):851-9. PubMed ID: 7901753
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the effects of polyamines on [125I]MK-801 binding to recombinant N-methyl-D-aspartate receptors.
Sharma TA; Reynolds IJ
J Pharmacol Exp Ther; 1999 May; 289(2):1041-7. PubMed ID: 10215685
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors.
Masuko T; Namiki R; Nemoto Y; Miyake M; Kizawa Y; Suzuki T; Kashiwagi K; Igarashi K; Kusama T
J Pharmacol Exp Ther; 2009 Nov; 331(2):522-30. PubMed ID: 19644042
[TBL] [Abstract][Full Text] [Related]
12. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex.
Bristow LJ; Hutson PH; Kulagowski JJ; Leeson PD; Matheson S; Murray F; Rathbone D; Saywell KL; Thorn L; Watt AP; Tricklebank MD
J Pharmacol Exp Ther; 1996 Nov; 279(2):492-501. PubMed ID: 8930150
[TBL] [Abstract][Full Text] [Related]
13. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
Ilyin VI; Whittemore ER; Guastella J; Weber E; Woodward RM
Mol Pharmacol; 1996 Dec; 50(6):1541-50. PubMed ID: 8967976
[TBL] [Abstract][Full Text] [Related]
14. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
[TBL] [Abstract][Full Text] [Related]
15. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
[TBL] [Abstract][Full Text] [Related]
16. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.
Malherbe P; Mutel V; Broger C; Perin-Dureau F; Kemp JA; Neyton J; Paoletti P; Kew JN
J Pharmacol Exp Ther; 2003 Dec; 307(3):897-905. PubMed ID: 14534359
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
Whittemore ER; Ilyin VI; Woodward RM
J Pharmacol Exp Ther; 1997 Jul; 282(1):326-38. PubMed ID: 9223571
[TBL] [Abstract][Full Text] [Related]
18. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission.
Frizelle PA; Chen PE; Wyllie DJ
Mol Pharmacol; 2006 Sep; 70(3):1022-32. PubMed ID: 16778008
[TBL] [Abstract][Full Text] [Related]
19. Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
Losi G; Lanza M; Makovec F; Artusi R; Caselli G; Puia G
Neuropharmacology; 2006 Mar; 50(3):277-85. PubMed ID: 16236334
[TBL] [Abstract][Full Text] [Related]
20. The pre-ischaemic neuroprotective effect of a novel polyamine antagonist, N1-dansyl-spermine in a permanent focal cerebral ischaemia model in mice.
Li J; Henman MC; Doyle KM; Strbian D; Kirby BP; Tatlisumak T; Shaw GG
Brain Res; 2004 Dec; 1029(1):84-92. PubMed ID: 15533319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
